Position:
Clinical Associate Professor
Division:
Cardiology
Education:
MD, Medical Academy of Lublin, Poland
FRCPC, University of Alberta, Cardiology
Recent Publications:

•Al Ali AM, Straatman LP, Allard MF, Ignaszewski AP.  Eosinophilic myocarditis: case series and review of literature. Can J.  Cardiol 2006;22(14):1233-7.
•Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A et al.  Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006; diagnosis and treatment.  Can J. Cardiol 2006;1:23-45.
•Dafna Rippel, Andrew Ignaszewski. Metabolic Syndrome: Why Should We Look For It?. Perspectives in Cardiology.2006 Vol 22 (5) 21.
•Dafna Rippel, Najeeb Jaha, Andrew Ignaszewski. Cardiovascular effects of Vitamins: Are They Really “Amines of Life?. Perspectives in Cardiology. 2006: Vol 22(6):29.
•Farias Godoy AN, Kwan CK, Ignaszewski A, Lear SA. Effectiveness of medication recommendation from a specialist clinic on primary care. Can J Cardiol 2006;22 (suppl D):160D.
•Lear SA, Spinelli JJ, Linden W, Brozic A, Kiess M, Frohlich JJ, Ignaszewski A.  The extensive lifestyle management intervention (ELMI) after cardiac rehabilitation: A four-year randomized controlled trial.  Am Heart J. 2006 Aug;152(2):333-9.
•SL Bar, E. Swiggum, L. Straatman, A. Ignaszewski. Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis. Can J Cardiol 2006 ,Vol 22:3 (263).
•”Ting LSL, Partovi N, Ignaszewski AP, Levy RD, Riggs KW, Ensom MHH. Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and
•Acyl-Glucuronide Metabolites in Stable Heart Transplant Recipients. Pharmacotherapy  2006;26:e87 (#229) (Abstract).”
•Arnold JM, Howlett JG, Dorian P. Ducharme A, Gianetti N, Haddad H, Heckman GA, Ignaszewski A.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation and use of biomarkers.  Can J Cardiol 2007;23(1):21-45.
•Chandavimol M. Malek F, Ignaszewski A.  Natural history of moderate to severe mitral regurgitation in patients with cardiomyopathy followed at tertiary care heart failure clinic.  Int J. Cardiol 2007;115(2):e68-70.
•Shalansky S, Lynd L, Richardson K, Ignaszewski, A. Kerr, C. The Risk of Warfarin-Related Bleeds and Supratherapeutic INR Associated With The Use of Complimentary and Alternative Medicines: A Longitudinal Analysis. Pharmacotherapy 2007 (in press).
•Ting LSL, Partovi N, Levy RD, Ignaszewski AP, Riggs KW, Ensom MHH.     Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and  Acyl-Glucuronide Metabolites in Stable Thoracic Transplant Recipients.  Pharmacotherapy (Abstract). Submitted June 2007.
•Ting LSL, Partovi N, Levy RD, Ignaszewski AP, Riggs KW, Ensom MHH. Limited      Sampling Strategies for Predicting Mycophenolate Area Under the Curve in Thoracic Transplant Recipients. Pharmacotherapy (Abstract). Submitted June 2007.
•Zutz A. Ignaszewski, A, Bates J, Lear SA. Utilization of the Internet to deliver cardiac rehabilitation at a distance: a pilot study. Telemed J E Health.2007 Jun:13(3);323-30.
•Chan S, Mancini GB, Ignaszewski A, Frohlich J.  Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio:  a randomized crossover study.  BMC Clin Pharmacology 2008:8:10.
•Dahri K, Shalansky S, Jang L, Jung L, Ignaszewski A, Clark C.  Accuracy of a Provincial Prescription Database for Assessing Medication Adherence in Heart Failure Patients.  The Annals of Pharmacotherapy 2008:42.
•Reichert S, Ignaszewski A.  Molecular and physiological effects of nesiritide.  Can J Cardiol 2008:24: 15B-18B.
•Sedlak T, Chandavimol M, Calleja A, Clark C, Edmonds M, Pu A, Humphries K, Ignaszewski A.  The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement.  Open Cardio Med Journal 2008:2:36-40.
•Chan S, Mancini GB, Ignaszewski A, Frohlich J.  Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio:  a randomized crossover study.  BMC Clin Pharmacology 2008:8:10.
•Dahri K, Shalansky S, Jang L, Jung L, Ignaszewski A, Clark C.  Accuracy of a Provincial Prescription Database for Assessing Medication Adherence in Heart Failure Patients.  The Annals of Pharmacotherapy 2008:42.
•Reichert S, Ignaszewski A.  Molecular and physiological effects of nesiritide.  Can J Cardiol 2008:24: 15B-18B.
•Sedlak T, Chandavimol M, Calleja A, Clark C, Edmonds M, Pu A, Humphries K, Ignaszewski A.  The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement.  Open Cardio Med Journal 2008:2:36-40.
•Bayliss M, Andrade  J, Heydari B, Ignaszewski AP. Jeremy Swan and the pulmonary atery catheter: Paving the way for effective hemodynamic monitoring. BC Medical Journal. Vol.51 NO. 7, 302-307, 2009.
•Lin D, Hollander Z, Ng RT, Imai C, Ignaszewski AP, Balshaw R, Freue G, Wilson-Mcmanus J, Qasimi P, Meredith A, Mui A, Triche T, McMaster R, Phil D, Keown PA, Mcmanus BM. Whole Blood Genomic Biomarkers of Acute Cardiac Allograft Rejection. The Journal of Heart and Lung Transplant. 2009, Vol. 28 NO. 09.
•M Al-Mohaissen, B Heilbron, J Leipsic, A Ignaszewski. Anomalous origin of the entire coronary system by three separate ostia within the right coronary sinus – a rarely observed anomaly. Can J. Cardiol Vol 26 No. 6 July 2010. Pages 206-209.
•Zsuzanna Hollander, David Lin, Virginia Chen, Raymond Ng, Janet Wilson-McManus, Andrew Ignaszewski, Gabreila Cohen Freu, Rob Balshaw, Alice Mui, Robert McMaster, Paul A. Keown and Bruce M. McManus for the NCE CECR PROOF Centre of Excellence. Whole Blood Biomarkers of Acute Cardiac Allograft Rejection: Double Crossing the Biopsy. Transplantjournal.com Volume 90, Number 12, December 27, 2010. Pages 1388-1393.